A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of SGC001 Injection in Chinese Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction and Planned for Primary Percutaneous Coronary Intervention (pPCI)
Latest Information Update: 02 Jan 2026
At a glance
- Drugs Dukiprubart (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Sponsors Beijing Sungen Biomedical Technology
Most Recent Events
- 02 Jan 2026 New trial record